Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer-Reference-Cited by-同舟云学术

Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer

Published:2024-07-02 Issue:10 Volume:25 Page:1335-1348
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Dutto Daniele¹,Livoti Simone¹,Soria Francesco¹,Gontero Paolo¹

Affiliation:

1. Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2380469

Reference60 articles.

1. IARC Cancer Today. Estimated number of new cases in 2020 worldwide both sexes all ages. 2021 [Internet]. [cited 2022 Mar 21]. Available from: https://gco.iarc.fr/today/online-analysis-table

2. Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer{star, open}. In: Maranchie J, editor. Urologic oncology: seminars and original investigations. Pittsburgh, Pennsylvania, United States of America: Elsevier Inc.; 2006. p. 344–348.

3. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

4. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

5. Ensuring Access to Injectable Generic Drugs — The Case of Intravesical BCG for Bladder Cancer